KR910000140A - 신장 질환 치료용 영양제제 - Google Patents
신장 질환 치료용 영양제제 Download PDFInfo
- Publication number
- KR910000140A KR910000140A KR1019900009129A KR900009129A KR910000140A KR 910000140 A KR910000140 A KR 910000140A KR 1019900009129 A KR1019900009129 A KR 1019900009129A KR 900009129 A KR900009129 A KR 900009129A KR 910000140 A KR910000140 A KR 910000140A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- ketoisocaproate
- keto
- suspended
- dissolved
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (12)
- 신부전증으로 고생하는 환자에게 유효 영양 용량의 하기 성분을 하기 중량%로 포함하는 조성물을 장내 또는 비경구 투여함을 특징으로 하여 신부전증으로 고생하는 환자를 양양 치료하는 방법.L-오르니틴-α-케토이소발레레이트 20 내지 25%L-오르니틴-α=케토이소캐프로에이트 20 내지 25%L-리신-α-케토-β메틸발레레이트 20 내지 25%L-히스티딘-α-케토이소캐프로에이트 5 내지 9% α-하이드록시-γ-메틸티로부티레이트의 칼슘염, 나트륨염 또는 칼륨염 1 내지 3%L-트립토판 0.1 내지 1%L-티로신 15 내지 20%L-트레오닌 3 내지 7%.
- 제1항에 있어서, 조성물을 저단백식이와 함께 투여하는 방법.
- 제1항에 있어서, 조성물을 투여하기 전에 수성 매질에 용해/현탁시키는 방법.
- 제1항에 있어서, 조성물을 투여하기 전에 향미제를 함유하는 수성 매질에 용해/현탁 시키는 방법.
- 제1항에 있어서, 조성물을 투여하기 전에 과일 쥬스에 용해/현탁시키는 방법.
- 신부전증으로 고생하는 환자에게 유효 영양 용량의 하기 성분을 하기 중량%로 포함하는 조성물을 장내 또는 비경구 투여함을 특징으로 하여 신부전증으로 고생하는 환자를 영양 치료하는 방법.L-오르티닌-α-케토이소발레레이트 20 내지 25%L-오르니틴-α-케토-메틸발레레이트 20 내지 25%L-리신-α-케토-케토이소캐프로에이트 20 내지 25%L-히스티딘-α-케토이소캐프로에이트 5 내지 9%-α-하이드록시-γ-메틸티로부티레이느의 칼슘염, 나트륨염 또는 칼륨염 1 내지 3%L-트립토판 0.1 내지 1%L-티로신 15 내지 20%L-트레오닌 3 내지 7%.
- 제6항에 있어서, 조성물을 저단백식이와 함께 투여는 방법.
- 제6항에 있어서, 조성물을 투여하기 전에 수성 매질에 용해/현탁시키는 방법.
- 제6항에 있어서, 조성물을 투여하기 전에 향미제를 함유하는 수성 매질에 용해/현탁 시키는 방법.
- 제6항에 있어서, 조성물을 투여하기 전에 과일 쥬스에 용해/현탁시키는 방법.
- 하기 중량%의 하기 성분의 혼합물로 이루어진 조성물.L-오르티닌-α-케토이소발레레이트 21 내지 25%L-오르니틴-α-케토이소캐프로에이트 21 내지 25%L-리신-α-케토-β-메틸발레레이트 21 내지 25%L-히스티딘-α-케토이소캐프로에이트 6 내지 8% α-하이드록시-γ-메틸티로부티레이트의 칼슘염, 나트륨염 또는 칼륨염 1.5 내지 2.5%L-트립토판 0.2 내지 0.75%L-티로신 16내지 19%L-트레오닌 4 내지 6%.
- 하기 중량%의 하기 성분의 혼합물로 이루어진 조성물.L-오르티닌-α-케토이소발레레이트 21 내지 24%L-오르니틴-α-케토-β-메틸발레레이트 21 내지 24%L-리신-α-케토-케토이소케프로에이트 21 내지 24%L-히스티딘-α-케토이소캐프로에이트 6 내지 8%-α-하이드록시-γ-메틸티로부티레이트의 칼슘염, 나트륨염 또는 칼륨염 1.5 내지 25%L-트립토판 0.2 내지 2.5%L-티로신 0.2내지 10.75%L-트레오닌 4 내지 6%.※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/369,163 US4957938A (en) | 1989-06-21 | 1989-06-21 | Nutritional formulation for the treatment of renal disease |
US369163 | 2006-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR910000140A true KR910000140A (ko) | 1991-01-29 |
Family
ID=23454347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900009129A KR910000140A (ko) | 1989-06-21 | 1990-06-21 | 신장 질환 치료용 영양제제 |
Country Status (9)
Country | Link |
---|---|
US (1) | US4957938A (ko) |
EP (1) | EP0405295B1 (ko) |
JP (1) | JPH0331211A (ko) |
KR (1) | KR910000140A (ko) |
AT (1) | ATE91392T1 (ko) |
AU (1) | AU627041B2 (ko) |
CA (1) | CA2019472A1 (ko) |
DE (1) | DE69002201T2 (ko) |
ES (1) | ES2058687T3 (ko) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5374651A (en) * | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
EP0663826B1 (en) * | 1991-09-27 | 1998-12-23 | Board Of Regents The University Of Texas System | Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies |
US5234696A (en) * | 1991-12-27 | 1993-08-10 | Abbott Laboratories | Method of producing tablets, tablets produced thereby, and method of treatment using same |
US5891459A (en) | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5576287A (en) * | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
JP3539970B2 (ja) * | 1994-10-07 | 2004-07-07 | フイルメニツヒ ソシエテ アノニム | フレーバリング組成物及びフレーバリング方法 |
AUPN115095A0 (en) * | 1995-02-15 | 1995-03-09 | Butt, Henry Lawrence | Analysis of and compositions and methods for the treatment of disease |
FR2775901B1 (fr) * | 1998-03-13 | 2000-07-21 | Logeais Labor Jacques | Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments |
US20050196470A9 (en) * | 1998-04-03 | 2005-09-08 | Wuh Hank C | Method and composition for enhancing sexual desire |
AU3221599A (en) * | 1998-04-03 | 1999-10-25 | Daily Wellness Company, The | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation |
US6288116B1 (en) | 1998-05-13 | 2001-09-11 | Novartis Nutrition Ag | Method of administration of a nutritional product to a person having renal failure |
JP2003501393A (ja) * | 1999-06-05 | 2003-01-14 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 心臓血管細胞増殖を阻害するための方法および組成物 |
US7696219B2 (en) * | 2000-09-27 | 2010-04-13 | Everett Laboratories, Inc. | Method and composition for supplementation of nutritional deficiences in renal patients |
US6995166B1 (en) | 2000-09-27 | 2006-02-07 | Everett Laboratories, Inc. | Method and composition for supplementation of nutritional deficiencies in renal patients |
US6989164B2 (en) * | 2000-12-22 | 2006-01-24 | The Daily Wellness Company | Method and composition for improving male fertility health |
US6497885B2 (en) * | 2000-12-22 | 2002-12-24 | The Daily Wellness Company | Method and composition for improving fertility health in female and male animals and humans |
FR2822704B1 (fr) * | 2001-03-29 | 2005-02-18 | Chiesi Sa | Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments |
WO2002081020A2 (en) * | 2001-04-04 | 2002-10-17 | Critical Therapeutics, Inc. | Method for preventing acute renal failure |
ITTO20020672A1 (it) * | 2002-07-26 | 2004-01-26 | Medestea Res And Production S | Composizioni farmaceutiche contenenti cheto-acidi per somministrazione endoperitoneale |
JP2007526316A (ja) * | 2004-03-01 | 2007-09-13 | ルーメン セラピューティックス リミテッド ライアビリティ カンパニー | 疾患を処置するための組成物および方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4100293A (en) * | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids |
GB1511302A (en) * | 1974-04-15 | 1978-05-17 | Univ Johns Hopkins | Pharmaceutical compositions comprising amino acid analogues |
US4320146A (en) * | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
US4352814A (en) * | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
US4296127A (en) * | 1979-04-18 | 1981-10-20 | The Johns Hopkins University | Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof |
US4677121A (en) * | 1985-01-22 | 1987-06-30 | The Johns Hopkins University | Method of inhibiting muscle protein degradation |
US4752619A (en) * | 1985-12-23 | 1988-06-21 | The Johns Hopkins University | Nutritional supplement for treatment of uremia |
FR2615734B1 (fr) * | 1987-05-27 | 1989-12-01 | Synthelabo | Compositions pharmaceutiques contenant un melange de sels de cetoacides et d'amino-acides utiles pour le traitement de l'uremie |
-
1989
- 1989-06-21 US US07/369,163 patent/US4957938A/en not_active Expired - Fee Related
-
1990
- 1990-06-19 EP EP90111519A patent/EP0405295B1/en not_active Revoked
- 1990-06-19 DE DE90111519T patent/DE69002201T2/de not_active Expired - Fee Related
- 1990-06-19 AT AT90111519T patent/ATE91392T1/de not_active IP Right Cessation
- 1990-06-19 ES ES90111519T patent/ES2058687T3/es not_active Expired - Lifetime
- 1990-06-20 AU AU57673/90A patent/AU627041B2/en not_active Ceased
- 1990-06-21 JP JP2163958A patent/JPH0331211A/ja active Pending
- 1990-06-21 CA CA002019472A patent/CA2019472A1/en not_active Abandoned
- 1990-06-21 KR KR1019900009129A patent/KR910000140A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0405295A2 (en) | 1991-01-02 |
JPH0331211A (ja) | 1991-02-12 |
ES2058687T3 (es) | 1994-11-01 |
US4957938A (en) | 1990-09-18 |
AU627041B2 (en) | 1992-08-13 |
DE69002201D1 (de) | 1993-08-19 |
CA2019472A1 (en) | 1990-12-21 |
ATE91392T1 (de) | 1993-07-15 |
DE69002201T2 (de) | 1994-01-05 |
EP0405295B1 (en) | 1993-07-14 |
AU5767390A (en) | 1991-01-03 |
EP0405295A3 (en) | 1991-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910000140A (ko) | 신장 질환 치료용 영양제제 | |
US3697287A (en) | Amino acid food composition | |
EP0705542B1 (en) | Adolescent dietary composition | |
US4368204A (en) | Nutrition composition for pediatrics | |
US4499076A (en) | Elemental diets for liver diseases | |
CA2404005C (en) | Composition comprising free amino acids | |
US5728678A (en) | Method and composition for providing nutrition to a renal failure patient | |
US4298601A (en) | Method and formulations for the treatment of obesity | |
US6544547B2 (en) | Nutritional composition containing methionine | |
AU2002230270B2 (en) | Rehydration composition | |
US3849554A (en) | Reduction of blood serum cholesterol | |
US3773930A (en) | Amino acid composition | |
Condon | Effect of dietary protein on symptoms and survival in dogs with an Eck fistula | |
JPH05213747A (ja) | 有機化合物における改良 | |
JP2014504261A (ja) | システイン及び食物摂取 | |
KR20050071562A (ko) | 글루타민을 제공하기 위한 방법 및 조성물 | |
JP2007197363A (ja) | 栄養補助剤 | |
EP0910253A1 (en) | Peri-operative drink | |
JP2683129B2 (ja) | 栄養組成物 | |
Leguina-Ruzzi et al. | Glutamine: a conditionally essential amino acid with multiple biological functions | |
CA3165947A1 (en) | Sleep dietary supplement | |
Jeevanandam et al. | Altered tissue polyamine levels due to ornithine-α-ketoglutarate in traumatized growing rats | |
CA2232134A1 (en) | Use of threonine for the treatment of phenylketonuria | |
KR0148573B1 (ko) | 생체 내계의 시스테인 농도를 증가시키는 방법 및 아미노산 수액 | |
Muggia‐Sullam et al. | Efficacy of two elemental diets: A pair feeding study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |